Regeneron is having difficulties again with its manufacturing partner Novo Nordisk, reporting that it expects two FDA ...

In honor of the annual World Lung Cancer Day commemoration on Aug. | In honor of the annual World Lung Cancer Day ...

Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...

GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

Merz Aesthetics has revamped its sales and marketing leadership, promoting an employee and hiring a vice president from GSK ...

As pharmaceutical import tariffs take shape in Europe, President Donald Trump is rounding out the week by spotlighting ...

Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

As for its neuroscience portfolio, AbbVie has added $300 million, putting its projection for the year at $10.5 billion, which ...